EA201100741A1 - Антитела к модифицированным пептидам ифр-1/е человека - Google Patents

Антитела к модифицированным пептидам ифр-1/е человека

Info

Publication number
EA201100741A1
EA201100741A1 EA201100741A EA201100741A EA201100741A1 EA 201100741 A1 EA201100741 A1 EA 201100741A1 EA 201100741 A EA201100741 A EA 201100741A EA 201100741 A EA201100741 A EA 201100741A EA 201100741 A1 EA201100741 A1 EA 201100741A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
igf
peptides
ifr
modified human
Prior art date
Application number
EA201100741A
Other languages
English (en)
Inventor
Джон Сюй
Юань Гао
Мара Форнаро
Райнер Хилленбранд
Франсуа Легай
Даниела Штёлльнер
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41466926&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201100741(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201100741A1 publication Critical patent/EA201100741A1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

В заявке описаны антитела с высокой специфичностью, которые способны различать модифицированные (например, чИФР-1/Еа 3mut) и эндогенные белки человека ИФР-1. Эти антитела обладают незначительной перекрестной реакционной способностью к чИФР-1 или чИФР-2 или не обладают ею. Они также обладают незначительной перекрестной реакционной способностью к ИФР-1 или ИФР-2 грызунов или не обладают ею. Эти антитела могут быть использованы в фармакокинетических (ФК)/фармакодинамических (ФД) оценках пептидов ИФР-1/Е, которые были введены людям или животным. С помощью метода сэндвич-ELISA с применением антител по настоящему изобретению в качестве антител-ловушек можно количественно оценить мутантные белки ИФР-1/Е в образцах.
EA201100741A 2008-11-10 2009-11-10 Антитела к модифицированным пептидам ифр-1/е человека EA201100741A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11295708P 2008-11-10 2008-11-10
PCT/EP2009/064947 WO2010052344A2 (en) 2008-11-10 2009-11-10 Antibodies to modified human igf-1/e peptides

Publications (1)

Publication Number Publication Date
EA201100741A1 true EA201100741A1 (ru) 2012-01-30

Family

ID=41466926

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100741A EA201100741A1 (ru) 2008-11-10 2009-11-10 Антитела к модифицированным пептидам ифр-1/е человека

Country Status (14)

Country Link
US (2) US8753632B2 (ru)
EP (1) EP2356148A2 (ru)
CN (1) CN102232087A (ru)
AU (1) AU2009312731B2 (ru)
BR (1) BRPI0921261A2 (ru)
CA (1) CA2743072A1 (ru)
CL (1) CL2011001028A1 (ru)
EA (1) EA201100741A1 (ru)
IL (1) IL212078A0 (ru)
MA (1) MA32770B1 (ru)
MX (1) MX2011004923A (ru)
NZ (1) NZ591918A (ru)
WO (1) WO2010052344A2 (ru)
ZA (1) ZA201102193B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
PE20120415A1 (es) 2008-12-12 2012-05-09 Boehringer Ingelheim Int Anticuerpos anti-igf
JP2011160696A (ja) * 2010-02-08 2011-08-25 Novartis Ag 修飾ヒトｉｇｆ−１／ｅペプチドに対する抗体
AR086250A1 (es) * 2011-05-05 2013-11-27 Hoffmann La Roche Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo
EP4005600A1 (en) 2012-04-26 2022-06-01 Yale University Cytotoxic-drug delivering molecules targeting hiv (cdm-hs), cytotoxic activity against the human immunodeficiency virus and methods of use
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
CN105622730B (zh) * 2016-02-18 2020-06-26 深圳华尔康生物科技有限公司 一种特异性结合igf-1的多肽及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924361B1 (en) * 1993-11-02 2005-08-02 Phosphoproteomics Llc Phosphopeptide-specific antibodies that are activity specific; methods of production and antibody uses
US5866688A (en) * 1995-06-06 1999-02-02 Oxford Biomedical Research, Inc. Production of anti-peptide antibodies against cytochrome P450
ATE503187T1 (de) 2004-12-23 2011-04-15 Hoffmann La Roche Nachweis eines therapeutischen antikörpers in einem versuchstier
ATE552853T1 (de) 2005-12-13 2012-04-15 Medimmune Ltd Proteine die spezifisch insulin-ähnliche wachstumsfaktoren binden, und deren anwendungen
BRPI0712052A2 (pt) * 2006-06-09 2012-01-10 Novartis Ag polipeptìdeos de fator de crescimento tipo insulina estabilizados
PE20120415A1 (es) 2008-12-12 2012-05-09 Boehringer Ingelheim Int Anticuerpos anti-igf

Also Published As

Publication number Publication date
CN102232087A (zh) 2011-11-02
AU2009312731A1 (en) 2010-05-14
NZ591918A (en) 2012-08-31
US20140243265A1 (en) 2014-08-28
US20110218145A1 (en) 2011-09-08
WO2010052344A2 (en) 2010-05-14
AU2009312731B2 (en) 2012-12-20
MA32770B1 (fr) 2011-11-01
ZA201102193B (en) 2011-12-28
WO2010052344A3 (en) 2010-10-28
CL2011001028A1 (es) 2011-10-07
IL212078A0 (en) 2011-06-30
US8753632B2 (en) 2014-06-17
BRPI0921261A2 (pt) 2018-10-23
CA2743072A1 (en) 2010-05-14
MX2011004923A (es) 2011-05-30
EP2356148A2 (en) 2011-08-17

Similar Documents

Publication Publication Date Title
EA201100741A1 (ru) Антитела к модифицированным пептидам ифр-1/е человека
EA202192103A1 (ru) Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1)
EA201100892A1 (ru) Белки, связывающиеся с cgrp-рецепторами человека
EA201891066A1 (ru) Антитела к ror1
NZ701444A (en) Antibodies to matrix metalloproteinase 9
EA201000471A1 (ru) Антигенсвязывающие белки, способные связывать тимусный стромальный лимфопоэтин
EA201500204A1 (ru) Антитела к ox40 и способы их применения
EA201791666A1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123
EA201001139A1 (ru) УЛУЧШЕННЫЕ АНТИТЕЛА АНТИ-TrkB
PE20141658A1 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3)
EA201291181A1 (ru) Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
AR084210A1 (es) PROTEINAS DE UNION AL TNF-a
NO20083053L (no) Humane monoklonale antistoffer mot O8E
AR078650A1 (es) Anticuerpo de union a il-1 beta
CO6400231A2 (es) Proteínas de unión a il-1
EA201490745A1 (ru) Полипептиды антител, которые вызывают антагонизм cd40l
UA113609C2 (xx) Антигензв'язуючий білок, який зв'язує людський il-23
BR112012018914A2 (pt) "anticorpo humanizado, proteína de ligação de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, proteína de ligação de anticorpo ou de antígeno, métodos para a produção de uma proteína de ligação de antígeno e para tratar um sujeito afetado por uma doença autoimune ou inflamatória, e, composição farmacêutica."
WO2011002968A3 (en) Polypeptides and method of treatment
EA201400488A1 (ru) Полипептидные конструкции и их применение
NO20091534L (no) Preparator og fremgangsmater som vedrorer glukagonreseptorantistoff
PE20150023A1 (es) Proteinas de union a antigeno st2
EA201790757A1 (ru) Связывающие антиген cd27l белки
WO2014114651A9 (en) Tnf-alpha antigen-binding proteins
EA200901436A1 (ru) Антигенсвязывающие белки, связывающие par-2